ZD-4522. Hypolipidemic, HMG-CoA reductase inhibitor

Drugs of the Future

Volumn 24, Issue 5, 1999, Pages 511-513

  Graul, A ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HYPERLIPIDEMIA; NONHUMAN; ORAL DRUG ADMINISTRATION; SHORT SURVEY;

EID: 0344780829     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1999.024.05.489462     Document Type: Short Survey

References (7)

1. Watanabe, M., Koike, H., Ishiba, T., Okada, T., Seo, S., Hirai, K. Synthesis and biological activity of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxy-6-heptenoates, a novel series of HMG-CoA reductase inhibitors. Bioorg Med Chem 1997, 5: 437-44.
2. Hirai, K., Ishiba, T., Koike, H., Watanabe, M. (Shionogi & Co., Ltd.). Pyrimidine derivs. as HMG-CoA reductase inhibitors. EP 521471, JP 93178841, US 5260440.
3. Sorbera, L.A., Leeson, P.A., Castañer, J. NK-104. Drugs Fut 1998, 23: 847-59.
4. Nezasa, K., Takeuchi, M., Yukawa, T., Kawahara, M., Inazawa, K., Hasegawa, H., Kaigaki, K., Nakano, M. Hepatic cell selectivity of novel HMG-CoA reductase inhibitor S-4522. Xenobiotic Metab Dispos 1998, 13(Suppl.): Abst 11P006.
5. Zeneca agreement with Shionogi on new cholesterol-lowering "superstatin" strengthens primary care franchise. Zeneca Pharmaceuticals Press Release Apr 21, 1998.
6. Zeneca accelerates phase III studies of cholesterol-lowering superstatin. Zeneca Pharmaceuticals Press Release Feb 15, 1999.
7. ZD-4522 development status. Zeneca Pharmaceuticals Company Communication Apr 27, 1999.